IL6 and congenital rubella syndrome: In cases of isolated ICANS, tocilizumab may not benefit, and there have been some concerns that it could in fact paradoxically increase CNS IL-6 levels, potentially aggravating ICANS [14, 16], This has led some treatment algorithms to recommend avoiding use of tocilizumab even when it coincides with CRS [46].